Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimepinostat - Curis

Next Previous
X
Search
Drug Profile

Fimepinostat - Curis

Alternative Names: CUDC-907

Latest Information Update: 21 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curis
  • Developer Curis; Dana-Farber Cancer Institute; National Cancer Institute (USA); University of California at San Francisco; Wayne State University School of Medicine
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Morpholines; Pyridines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Thyroid cancer
  • Phase I Anaplastic astrocytoma; CNS cancer; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Lymphoma; Medulloblastoma; Solid tumours
  • No development reported Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 21 Mar 2024 Phase-I development in Anaplastic-astrocytoma, Glioma, Glioma, Medulloblastoma (In adolescents, In children, Late-stage disease, Recurrent, Second-line therapy or greater, In adults) is ongoing in USA (PO) (NCT03893487)
  • 21 Mar 2024 Phase-I development in CNS cancer, Lymphoma and Solid tumours (In infants, In children, In adolescents, In adults, Second-line therapy or greater) is ongoing in USA (PO) (NCT02909777)
  • 21 Mar 2024 Phase-I development in Diffuse intrinsic pontine glioma (In adolescents, In children, Late-stage disease, First-line therapy, In adults) is ongoing in USA (PO) (NCT03893487)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top